Working with manual cell culture introduces unavoidable operator-dependent variability, inconsistent passaging intervals, irregular media exchange timing, and fatigue-driven errors, that fundamentally compromises reproducibility. At the same time, manual workflows simply cannot match the throughput demands of modern drug screening campaigns or the technical complexity of long-term 3D organoid culture.
For organoid models alone, culture protocols can span over 100 days of continuous, precise feeding and monitoring. Approximately 70% of experimental variability in organoid assays has been attributed to manual handling inconsistencies. For high-throughput drug sensitivity screens, consistent and uniform cell supply across thousands of wells is an absolute prerequisite, one that no manual team can reliably sustain over time.
A first step toward overcoming these challenges is to transition individual process steps, such as media exchange, passaging, or imaging, to automated platforms. The final goal is a fully integrated, AI-orchestrated workflow that manages every stage of the culture cycle end-to-end, dramatically increasing throughput, traceability, and biological fidelity.
We have partnered with a company offering a hand-picked portfolio of AI-based automated cell culture systems, developed by scientists for scientists, to eliminate process variability and deliver the consistent, high-quality data your research demands.
